PAN AIR analysis of the NASA/MCAIR 279-3: An advanced supersonic V/STOL fighter/attack aircraft

PAN AIR is a computer program for predicting subsonic or supersonic linear potential flow about arbitrary configurations. The program was applied to a highly complex single-engine-cruise V/STOL fighter/attack aircraft. Complexities include a close-coupled canard/wing, large inlets, and four exhaust nozzles mounted directly under the wing and against the fuselage. Modeling uncertainties involving canard wake location and flow-through approximation through the inlet and the exhaust nozzles were investigated. The recently added streamline capability of the program was utilized to evaluate visually the predicted flow over the model. PAN AIR results for Mach numbers of 0.6, 0.9, and angles of attack of 0, 5, and 10 deg. were compared with data obtained in the Ames 11- by 11-Foot Transonic Wind tunnel, at a Reynolds number of 3.69 x 10 to the 6th power based on c bar

Sonic boom prediction for the Langley Mach 2 low-boom configuration

Sonic boom pressure signatures and aerodynamic force data for the Langley Mach 2 low sonic boom configuration were computed using the TranAir full-potential code. A solution-adaptive Cartesian grid scheme is utilized to compute off-body flow field data. Computations were performed with and without nacelles at several angles of attack. Force and moment data were computed to measure nacelle effects on the aerodynamic characteristics and sonic boom footprints of the model. Pressure signatures were computed both on and off ground-track. Near-field pressure signature computations on ground-track were in good agreement with experimental data. Computed off ground-track signatures showed that maximum pressure peaks were located off ground-track and were significantly higher than the signatures on ground-track. Bow shocks from the nacelle inlets increased lift and drag, and also increased the magnitude of the maximum pressure both on and off ground-track

TranAir: Recent advances and applications

TranAir is a computer code which solves the full-potential equation for transonic flow about very general and complex configurations. Piecewise flat surface panels are used to describe the surface geometry. This paneled definition is then embedded in an unstructured cartesian flow field grid. Finite elements are used in the discretization of the flow field grid in a manner which is fully conservative and second-order accurate. Since geometries may be defined with relative ease, and since the user is not involved in the generation of the flow field grid, computational results may be generated rather quickly for a wide range of geometries. For transonic cases in the cruise angle-of-attack range, TranAir has generated results which are in generally good agreement with both Euler results and wind tunnel data. A typical transonic case runs in 1 to 2 CPU hours on a Cray X-MP. For subcritical cases, the code runs in 15 to 30 CPU minutes, even for geometries in which several thousand surface panels are used in the definition. This ability to rapidly and accurately provide both subsonic and transonic predictions about very complex aircraft configurations gives TranAir the potential of being a very powerful and widely used design tool

Aerodynamic analysis of three advanced configurations using the TranAir full-potential code

Computational results are presented for three advanced configurations: the F-16A with wing tip missiles and under wing fuel tanks, the Oblique Wing Research Aircraft, and an Advanced Turboprop research model. These results were generated by the latest version of the TranAir full potential code, which solves for transonic flow over complex configurations. TranAir embeds a surface paneled geometry definition in a uniform rectangular flow field grid, thus avoiding the use of surface conforming grids, and decoupling the grid generation process from the definition of the configuration. The new version of the code locally refines the uniform grid near the surface of the geometry, based on local panel size and/or user input. This method distributes the flow field grid points much more efficiently than the previous version of the code, which solved for a grid that was uniform everywhere in the flow field. TranAir results are presented for the three configurations and are compared with wind tunnel data

The Time is Right for an Antarctic Biorepository Network

Antarctica is a central driver of the Earth’s climate and health. The Southern Ocean surrounding Antarctica serves as a major sink for anthropogenic CO2 and heat (1), and the loss of Antarctic ice sheets contributes significantly to sea level rise and will continue to do so as the loss of ice sheets accelerates, with sufficient water stores to raise sea levels by 58 m (2). Antarctica\u27s marine environment is home to a number of iconic species, and the terrestrial realm harbors a remarkable oasis for life, much of which has yet to be discovered (3). Distinctive oceanographic features of the Southern Ocean—including the Antarctic Circumpolar Current, the Antarctic Polar Front, and exceptional depths surrounding the continent—coupled with chronically cold temperatures have fostered the evolution of a vast number of uniquely coldadapted species, many of which are found nowhere else on the Earth (4). The Antarctic marine biota, for example, displays the highest level of species endemism on the Earth (5). However, warming, ocean acidification, pollution, and commercial exploitation threaten the integrity of Antarctic ecosystems (6). Understanding changes in the biota and its capacities for adaptation is imperative for establishing effective policies for mitigating the impacts of climate change and sustaining the Antarctic ecosystems that are vital to global health

Evaluation of serological cross-reactivity and cross-neutralization between the United States porcine epidemic diarrhea virus prototype and S-INDEL-variant strains

BACKGROUND: At least two genetically different porcine epidemic diarrhea virus (PEDV) strains have been identified in the United States (U.S. PEDV prototype and S-INDEL-variant strains). The current serological assays offered at veterinary diagnostic laboratories for detection of PEDV-specific antibody are based on the U.S. PEDV prototype strain. The objectives of this study were: 1) isolate the U.S. PEDV S-INDEL-variant strain in cell culture; 2) generate antisera against the U.S. PEDV prototype and S-INDEL-variant strains by experimentally infecting weaned pigs; 3) determine if the various PEDV serological assays could detect antibodies against the U.S. PEDV S-INDEL-variant strain and vice versa. RESULTS: A U.S. PEDV S-INDEL-variant strain was isolated in cell culture in this study. Three groups of PEDV-negative, 3-week-old pigs (five pigs per group) were inoculated orally with a U.S. PEDV prototype isolate (previously isolated in our lab), an S-INDEL-variant isolate or virus-negative culture medium. Serum samples collected at 0, 7, 14, 21 and 28 days post inoculation were evaluated by the following PEDV serological assays: 1) indirect fluorescent antibody (IFA) assays using the prototype and S-INDEL-variant strains as indicator viruses; 2) virus neutralization (VN) tests against the prototype and S-INDEL-variant viruses; 3) PEDV prototype strain whole virus based ELISA; 4) PEDV prototype strain S1-based ELISA; and 5) PEDV S-INDEL-variant strain S1-based ELISA. The positive antisera against the prototype strain reacted to and neutralized both prototype and S-INDEL-variant viruses, and the positive antisera against the S-INDEL-variant strain also reacted to and neutralized both prototype and S-INDEL-variant viruses, as examined by IFA antibody assays and VN tests. Antibodies against the two PEDV strains could be detected by all three ELISAs although detection rates varied to some degree. CONCLUSIONS: These data indicate that the antibodies against U.S. PEDV prototype and S-INDEL-variant strains cross-reacted and cross-neutralized both strains in vitro. The current serological assays based on U.S. PEDV prototype strain can detect antibodies against both U.S. PEDV strains

Isolated familial somatotropinoma: 11q13-loh and gene/protein expression analysis suggests a possible involvement of aip also in non-pituitary tumorigenesis

OBJECTIVE: Non-pituitary tumors have been reported in a subset of patients harboring germline mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene. However, no detailed investigations of non-pituitary tumors of AIP-mutated patients have been reported so far. PATIENTS: We examined a MEN1- and p53-negative mother-daughter pair with acromegaly due to somatotropinoma. Subsequently, the mother developed a large virilizing adrenocortical carcinoma and a grade II B-cell non-Hodgkin's lymphoma. DESIGN: Mutational analysis was performed by automated sequencing. Loss-of-heterozygosity (LOH) analysis was carried out by sequencing and microsatellite analysis. AIP expression was assessed through quantitative PCR (qPCR) and immunohistochemistry. RESULTS: The functional inactivating mutation c.241C>T (R81X), which blocks the AIP protein from interacting with phosphodiesterase 4A (PDE4A), was identified in the heterozygous state in the leukocyte DNA of both patients. Analyzing the tumoral DNA revealed that the AIP wild-type allele was lost in the daughter's somatotropinoma and the mother's adrenocortical carcinoma. Both tumors displayed low AIP protein expression levels. Low AIP gene expression was confirmed by qPCR in the adrenocortical carcinoma. No evidence of LOH was observed in the DNA sample from the mother's B-cell lymphoma, and this tumor displayed normal AIP immunostaining. CONCLUSIONS: Our study presents the first molecular analysis of non-pituitary tumors in AIP-mutated patients. The finding of AIP inactivation in the adrenocortical tumor suggests that further investigation of the potential role of this recently identified tumor suppressor gene in non-pituitary tumors, mainly in those tumors in which the cAMP and the 11q13 locus are implicated, is likely to be worthwhile

Asfotase alfa therapy for children with hypophosphatasia

Background. Hypophosphatasia (HPP) is caused by loss-of-function mutation(s) of the gene that encodes the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP). Consequently, cell-surface deficiency of TNSALP phosphohydrolase activity leads to extracellular accumulation of inorganic pyrophosphate, a natural substrate of TNSALP and inhibitor of mineralization. Children with HPP can manifest rickets, skeletal pain, deformity, fracture, muscle weakness, and premature deciduous tooth loss. Asfotase alfa is a recombinant, bone-targeted, human TNSALP injected s.c. to treat HPP. In 2012, we detailed the 1-year efficacy of asfotase alfa therapy for the life-threatening perinatal and infantile forms of HPP. Methods. Here, we evaluated the efficacy and safety of asfotase alfa treatment administered to children 6–12 years of age at baseline who were substantially impaired by HPP. Two radiographic scales quantitated HPP skeletal disease, including comparisons to serial radiographs from similarly affected historical control patients. Results. Twelve children receiving treatment were studied for 5 years. The 6-month primary endpoint was met, showing significant radiographic improvement. Additional significant improvements included patient growth, strength, motor function, agility, and quality of life, which for most patients meant achieving normal values for age- and sex-matched peers that were sustained at 5 years of treatment. For most, pain and disability resolved. Mild to moderate injection-site reactions were common and were sometimes associated with lipohypertrophy. Low anti–asfotase alfa antibody titers were noted in all patients. No evidence emerged for clinically important ectopic calcification or treatment resistance. Conclusions. Asfotase alfa enzyme replacement therapy has substantial and sustained efficacy with a good safety profile for children suffering from HPP. Trial Registration. ClinicalTrials.gov NCT00952484 (https://clinicaltrials.gov/ct2/show/NCT00952484) and NCT01203826 (https://clinicaltrials.gov/ct2/show/NCT01203826). Funding. Alexion Pharmaceuticals Inc. and Shriners Hospitals for Children

IceCube - the next generation neutrino telescope at the South Pole

IceCube is a large neutrino telescope of the next generation to be constructed in the Antarctic Ice Sheet near the South Pole. We present the conceptual design and the sensitivity of the IceCube detector to predicted fluxes of neutrinos, both atmospheric and extra-terrestrial. A complete simulation of the detector design has been used to study the detector's capability to search for neutrinos from sources such as active galaxies, and gamma-ray bursts.Comment: 8 pages, to be published with the proceedings of the XXth International Conference on Neutrino Physics and Astrophysics, Munich 200